HRTX News and Press, Heron Therapeutics Inc. From 10/05/21

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

Heron Therapeutics Announces Filing of a Supplemental New Drug Application for Significant Expansion of ZYNRELEF® Indication Statement Based on Successful Outcome of FDA Type C Meeting - FDA agreed to the immediate filing of supplemental NDA to significantly expand the ZYNR...

“No pain, no gain” is a motivational gym saying used for years. Investors have found the saying also applies to portfolio gains. The pain management industry is rapidly growing and now provides an even broader spectrum of publicly traded opportunities. Why? Reduced opioid use has...

NobleCon Online Investor Event - New Developments in Pain Management - October 7, 2021 Exclusively on Channelchek - Featuring Baudax Bio (BXRX), BioElectronics Corporation (BIEL), Heron Therapeutics (HRTX), MedX Health (MDXHF), NanoVibronix (NAOV), Virpax Pharmaceuticals (VRPX) Read More >...

Heron Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference PR Newswire SAN DIEGO , Sept. 21, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of p...

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate Updates - ZYNRELEF® Commercially Launched on July 1, 2021 with 61 Unique Accounts Already Purchasing the Product and Multiple Commercial and Medic...

Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients Experiencing an Opioid-free Recovery PR Newswire SAN DIEGO ,...

Heron Therapeutics Inc. (NASDAQ:HRTX) traded today at a new 52-week low of $12.20. Approximately 223,000 shares have changed hands today, as compared to an average 30-day volume of 1.4 million shares. Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on im...

Heron Therapeutics (HRTX) posts new analysis evaluating the efficacy and safety of ZYNRELEF extended-release solution in adults aged 65 years and older undergoing bunionectomy and hernia repair from the Phase 3 EPOCH 1 and EPOCH 2 studies.The analysis showed that 58% of bunionectomy and 87% o...